The MEK1/2 inhibitor binimetinib also inhibited CLL survival induced by stroma-conditioned media and phorbol myristylate (PMA) when used alone or in combination with venetoclax [161]. Here, MAP2K1 is linked to B-cell chronic lymphocytic leukemia.